• Wunna Wunna, Jovanna Tsoutsouki, Aisha Chowdhury, and Tahseen Ahmad Chowdhury.
• Department of Diabetes, The Royal London Hospital, London, UK.
• Postgrad Med J. 2021 Jun 1; 97 (1148): 384-390.

AbstractType 1 diabetes (T1D) is an autoimmune condition that affects a significant number of people worldwide, with higher prevalence in white European populations. The condition is responsible for a high burden of microvascular complications, especially when poorly controlled. The condition is also burdensome on the patient and has major psychosocial and occupational impacts. It requires lifelong frequent blood glucose monitoring and regular insulin injections. Important technological advances in the management of T1D have occurred in recent years. These include the advent of new glucose testing devices using interstitial glucose, and new insulin delivery devices. These technologies may improve quality of life, and glucose management in this condition. This review aims to outline the current advances in the management of T1D for the general physician, with a particular focus on new technologies.© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

18 keywords...

hide…